NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
NEXGEL, Inc. has closed the acquisition of a regenerative biomaterial product portfolio from Celularity Inc., financed by a $5.5 million strategic investment led by Sequence LifeScience. This transaction is expected to nearly triple NEXGEL’s annual revenue to approximately $35 million and be immediately accretive to profitability. The company has l…